Publications

• Research Article
  A Clinical Phase II Study of Sorafenib in Advanced Hepatocellular Carcinoma
  Author(s): Hanan Shawky Gamal El Deen and Emad Abd-Elmongy SadakaHanan Shawky Gamal El Deen and Emad Abd-Elmongy Sadaka
  
  Purpose:Sorafenib is an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor and Raf with demonstrated efficacy as first-line therapy for patients with inoperable hepatocellular carcinoma (HCC). We reported the preliminary results of this treatment to evaluate its safety, tolerability, and efficacy in patients with inoperable HCC. Patients and Methods: Patients with inoperable HCC and a Karnofsky performance status (KPS) of ≥70, Child-Pugh (CP) score of A or B, an elevated alphafetoprotein (AFP) level and adequate hematologic, renal and hepatic functions; were enrolled. No Prior therapy was permitted. The regimen was sorafenib at a dose of 400 mg bid, given 7 days per week. Treatment was maintained until disease progression or unacceptable toxicity. Res.. Read More»
  DOI: 10.4172/2161-1173.1000101

  Abstract PDF